This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and management of secondary tumours (metastatic disease).
A table of NHS England interim treatment regimens gives possible alternative treatment options for use during the COVID-19 pandemic to reduce infection risk. This may affect decisions for patients with colorectal cancer. See the COVID-19 rapid guideline: delivery of systemic anticancer treatments for more details.
This guideline includes recommendations on:
- prevention of colorectal cancer in people with Lynch syndrome
- information for people with colorectal cancer
- management of local disease
- molecular biomarkers to guide systemic anti-cancer therapy
- management of metastatic disease
- ongoing care and support
Who is it for?
- Healthcare professionals
- Cancer Alliances Commissioners of colorectal cancer preventative and treatment services (including Clinical Commissioning Groups and NHS England Specialised Commissioning)
- People with colorectal cancer and their families and carers
Is this guideline up to date?
We checked the impact of the 10-year follow-up of the CAPP2 study on this guideline in July 2020. We will not update the guideline at this time.
Guideline development process
This guideline updates and replaces NICE guideline CG131 (November 2011) and NICE guideline CSG5 (June 2004)
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.